P-glycoprotein expression and pharmacoresistant epilepsy: Cause or consequence?

Epilepsy Currents

Volumn 14, Issue 3, 2014, Pages 136-138

  Gidal, Barry E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; MULTIDRUG RESISTANCE PROTEIN; VERAPAMIL;

ARTICLE; BLOOD BRAIN BARRIER; DRUG UPTAKE; EPILEPSY; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; PROTEIN EXPRESSION;

EID: 84904706182     PISSN: 15357597     EISSN: 15357511     Source Type: Journal    
DOI: 10.5698/1535-7597-14.3.136     Document Type: Article

References (16)

1. Kwan P, Schachter S, Brodie M. Drug resistant epilepsy. N Engl J Med 2011; 365:919-926.
2. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995; 36:1-6.
3. Ste{ogonek}pień K, Tomaszewski M, Tomaszewska J, Czuczwar S. The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs. Pharmacol Rep 2012; 64:1011-1019.
4. Loscher W, Potschaka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005; 76:22-76.
5. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam, and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2007; 52:333-346.
6. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: Expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002; 125:22-31.
7. Aronica E, Gorter JA, Jansen GH, van Veelen CW, van Rijen PC, Leenstra S, Ramkema M, Scheffer GL, Scheper RJ, Troost D. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: Focal cortical dysplasia and glioneuronal tumors. Neuroscience 2003; 118:417-429.
8. Kubota H, Ishihara H, Langmann T, Schmidz G, Stieger B, Wieser HG, Yonekawa Y, Frei K. Distribution and functional activity of Pglycoprotein and multidrug resistance-associated proteins in human microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res 2006;213-228.
9. Anderson GD, Shen DD. Where is the evidence that P-glycoprotein limits brain uptake of antiepileptic drug and contributes to drug resistance in epilepsy? Epilepsia 2007;48:2372-2374.
10. Haerian BS, Roslan H, Raymond A, Tan CT, Lim KS, Zulfiki SZ, Mohamed EHM, Tan HJ, Mohamed Z. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: A systematic review and meta-analysis. Seizure 2010; 19:339-346.
11. Ambroziak K, Kuteykin-Tepyakov K, Luna-Tortos C, Al-Falah M, Fedrowitz M, Loscher W. Exposure to antiepileptic drugs does not alter the functionality of P-glycoprotein in brain capillary endothelial and kidney cell lines. Eur J Pharmacol 2010; 628:57-66.
12. Liu JY, Thom M, Catarino CB, Martinian L, Figarella-Branger D, Bartolomei F, Koepp M, Sisodiya SM. Neuropathology of the bloodbrain barrier and pharmacoresistance in human epilepsy. Brain 2012;135;3115-3133.
13. Potschaka H. Modulating P-glycoprotein regulation: Future perspectives for pharmacoresistant epilepsies? Epilepsia 2010;51:1333-1347.
14. Lombardo L, Pelliteri R, Balazy M, Cardile V. Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr Neurovasc Res 2008; 5:82-92.
15. Owen A, Goldring C, Morgan P, Park BK, Pirohamed M. Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin:the role of nuclear hormone response elements. Br J Clin Pharmacol 2008; 62:237-242.
16. French JA. P-glycoprotein expression and antiepileptic drug resistance. Neurology 2013;12732-12733.